MDxHealth SA Ordinary Shares (MDXH) — 分析摘要
MDxHealth SA Ordinary Shares（MDXH）的市值为68.84百万美元，最近一年的营收同比增长了+19.8%。净利润率为-31.1%。当前市盈率为-2.1倍。
核心要点
- 营收同比变化+19.8%
- 净利润率-31.1%
- 市盈率-2.1倍
MDXH的营收增长为+19.8%，市盈率为-2.1倍。
MDxHealth SA Ordinary Shares (MDXH)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -18.3x — 盈利不足以覆盖利息支出
股东权益为负，可能意味着资产负债表承压。
营业利润率为 -13.4% — 经营亏损显著
净利率为 -31.1% — 亏损显著
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
员工人数
364
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。